The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen
- 2 February 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 119 (5), 1302-1313
- https://doi.org/10.1182/blood-2011-08-376038
Abstract
Lewis Y Ag (LeY) is a cell-surface tetrasaccharide that participates in angiogenesis. Recently, we demonstrated that LeY is a specific ligand of the recombinant lectin-like domain of thrombomodulin (TM). However, the biologic function of interaction between LeY and TM in endothelial cells has never been investigated. Therefore, the role of LeY in tube formation and the role of the recombinant lectin-like domain of TM—TM domain 1 (rTMD1)—in antiangiogenesis were investigated. The recombinant TM ectodomain exhibited lower angiogenic activity than did the recombinant TM domains 2 and 3. rTMD1 interacted with soluble LeY and membrane-bound LeY and inhibited soluble LeY-mediated chemotaxis of endothelial cells. LeY was highly expressed on membrane ruffles and protrusions during tube formation on Matrigel. Blockade of LeY with rTMD1 or Ab against LeY inhibited endothelial tube formation in vitro. Epidermal growth factor (EGF) receptor in HUVECs was LeY modified. rTMD1 inhibited EGF receptor signaling, chemotaxis, and tube formation in vitro, and EGF-mediated angiogenesis and tumor angiogenesis in vivo. We concluded that LeY is involved in vascular endothelial tube formation and rTMD1 inhibits angiogenesis via interaction with LeY. Administration of rTMD1 or recombinant adeno-associated virus vector carrying TMD1 could be a promising antiangiogenesis strategy.Keywords
This publication has 38 references indexed in Scilit:
- Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory responseBlood, 2008
- The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritisJournal of Thrombosis and Haemostasis, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanismJCI Insight, 2005
- Evidence of Human Thrombomodulin Domain as a Novel Angiogenic FactorCirculation, 2005
- The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase PathwaysThe Journal of Experimental Medicine, 2002
- Separation and Characterization of the Molecular Species of Thrombomodulin in the Plasma of Diabetic PatientsThrombosis Research, 2001
- Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancerInternational Journal of Cancer, 1996
- Purification and characterization of two forms of soluble thrombomodulin from human urineJBIC Journal of Biological Inorganic Chemistry, 1994
- Thrombomodulin is present in human plasma and urine.JCI Insight, 1985